Nuron, PolyTherics in deal for MS candidate

Nuron Biotech Inc. (Exton, Pa.) will use TheraPEG site-specific PEGylation technology from PolyTherics Ltd. (London, U.K.) to develop a long-acting version of NU100, a recombinant interferon beta-1b in development for relapsing-remitting multiple sclerosis (MS). Once Nuron determines an appropriate polyethylene glycol (PEG) polymer for attachment to NU100, the autoimmune company will have an option to license PolyTherics' technology for development and commercialization of the long-acting formulation, which will be named NU400. Financial terms were not disclosed. ...